The Greater Cannabis Company, Inc. (GCAN)

Overview

The Greater Cannabis Company, Inc., founded in 2014 and based in Baltimore, Maryland, is at the forefront of developing and commercializing cannabinoid therapeutics. Through its innovative approach, the company focuses on creating products that enhance the bioavailability of cannabinoids and address a range of neuropsychiatric disorders. Leveraging a license agreement with Shaare Zedek Scientific Ltd., The Greater Cannabis Company is particularly focused on novel treatments for conditions such as autism, schizophrenia, Parkinson's disease, Alzheimer's disease, among others.

Products and Services

• Oral Transmucosal Patch Platform:

This platform represents the company’s main product line - a cutting-edge delivery system designed for the efficient absorption of cannabinoids. The oral transmucosal patch is applied to the inner cheek area, where the buccal mucosa facilitates the direct absorption of actives into the bloodstream. This method of delivery not only ensures a faster onset of effects but also enhances the bioavailability of cannabinoids, making it an effective alternative to traditional methods of ingestion.

• Neuropsychiatric Disorder Therapeutics:

Under the license agreement with Shaare Zedek Scientific Ltd., The Greater Cannabis Company is developing cannabinoid-based therapeutics aimed at treating a spectrum of neuropsychiatric disorders. These include autism, schizophrenia, Parkinson's disease, and Alzheimer's disease. The research and development efforts are grounded in the belief that cannabinoids, through targeted delivery systems like the oral transmucosal patch, can offer significant improvements in the treatment and management of these complex disorders.